Intent to Sole Source - Reagents and Consumables required for Systemic Autoimmune Rheumatic Diseases.

The National Institutes of Health (NIH), Office of Purchasing and Contracts, on behalf of the Critical Care Medicine Department, intends to award a firm-fixed-priced sole source contract to 10X Genomics, Inc. This acquisition, identified under solicitation number NOI-CC-OLAO-26-006103, is for the procurement of reagents and consumables required for research into Systemic Autoimmune Rheumatic Diseases. The requirement is classified under NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC 6550 IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS. There is no set-aside assigned to this notice.

The NIH is citing the statutory authority of 41 U.S.C. 253(c)(1) as implemented by FAR 6.302-1, as 10X Genomics, Inc. is identified as the only responsible source capable of satisfying the agency’s specific requirements. Performance will be conducted at the NIH facilities in Bethesda, Maryland. One attachment, a Justification for Other Than Full and Open Competition (JOFOC) document, was posted with the notice on May 18, 2026.

While this notice does not constitute a request for proposal, the government will consider capability statements from responsible sources to determine if the requirement should be competed. Capability statements must be submitted by 12:00 PM Eastern Standard Time on June 2, 2026. The determination to compete the requirement based on received responses remains at the discretion of the government.